Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery
Launched by RADIATION THERAPY ONCOLOGY GROUP · Jun 9, 2004
Trial Information
Current as of March 16, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Evaluate locoregional control rates, patterns of first failure, and overall and disease-free survival in patients with advanced squamous cell carcinoma of the head and neck at high risk of locoregional recurrence who are treated postoperatively with concurrent cisplatin and radiotherapy. II. Compare the toxicity of concurrent chemoradiotherapy vs. radiotherapy alone in the postoperative setting.
OUTLINE: Randomized study. Arm I: Radiotherapy. Involved-field irradiation using Co60, 1-6 MV photons, or electrons. Arm II: Radiotherapy plus Single-Agent Chemotherapy. Irradiation ...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Biopsy-proven squamous cell carcinoma of one of the following sites: Hypopharynx Larynx Oral cavity Oropharynx At least 1 of the following high-risk factors required: Histologic extracapsular nodal extension Histologic involvement of 2 or more regional lymph nodes Microscopically positive mucosal margins Complete resection of all visible and palpable disease Therapy must begin within 8 weeks of tumor-related surgery Bilateral resections may or may not be performed simultaneously Eligibility window begins with first definitive surgery Neck dissection not required for T4 N0, truly midline supraglottic tumors No tumors of the lip, nasopharynx, or sinuses No synchronous or concurrent head and neck tumors No evidence of distant metastasis Concurrent registration on Fixed Tumor Repository Study allowed
- • PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100% Hematopoietic: WBC at least 3,500 Platelets at least 100,000 Hepatic: Not specified Renal: Creatinine clearance greater than 50 mL/min Other: No medical contraindication to protocol therapy No second malignancy within 5 years No pregnant or nursing women
- • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head and neck region Surgery: See Disease Characteristics
Trial Officials
Jay S. Cooper, MD, FACR, FACRO
Study Chair
NYU Langone Health
James N. Endicott, MD, PA
Study Chair
H. Lee Moffitt Cancer Center and Research Institute
Julie A. Kish, MD, FACP
Study Chair
Josephine Ford Cancer Center
About Radiation Therapy Oncology Group
The Radiation Therapy Oncology Group (RTOG) is a leading clinical trial sponsor dedicated to advancing the field of radiation oncology through rigorous research and collaboration. Established to improve patient outcomes, RTOG conducts multicenter clinical trials that evaluate innovative radiation treatment techniques, assess the efficacy of combined modality therapies, and enhance quality of life for cancer patients. Committed to scientific excellence, RTOG fosters partnerships among academic institutions, healthcare providers, and industry stakeholders, ensuring that findings translate into clinical practice to optimize cancer care and improve survival rates.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Indianapolis, Indiana, United States
Minneapolis, Minnesota, United States
Cleveland, Ohio, United States
Omaha, Nebraska, United States
Decatur, Georgia, United States
Peoria, Illinois, United States
Urbana, Illinois, United States
Des Moines, Iowa, United States
Kalamazoo, Michigan, United States
Saint Louis Park, Minnesota, United States
Hackensack, New Jersey, United States
Pretoria, , South Africa
Duluth, Minnesota, United States
Nashville, Tennessee, United States
Cedar Rapids, Iowa, United States
Toledo, Ohio, United States
Milwaukee, Wisconsin, United States
Evanston, Illinois, United States
Nashville, Tennessee, United States
Tulsa, Oklahoma, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials